Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 45 publications
High-Dose Chemotherapy for Multiply or Poor-Risk Relapsed Germ Cell Tumors.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 29, 2025
Randomized Phase 2 Trial of Presurgical Androgen Deprivation Therapy With or Without Axitinib in Prostate Cancer Presenting With Lymph Node Metastasis.
Journal: European urology oncology
Published: March 31, 2025
Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors.
Journal: Clinical genitourinary cancer
Published: May 07, 2024
Integrative Molecular Analyses of the MD Anderson Prostate Cancer Patient-derived Xenograft (MDA PCa PDX) Series.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: August 15, 2023
External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 11, 2023
Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 29, 2021
Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience.
Journal: International journal of cancer
Published: November 13, 2020
The MD Anderson Prostate Cancer Patient-derived Xenograft Series (MDA PCa PDX) Captures the Molecular Landscape of Prostate Cancer and Facilitates Marker-driven Therapy Development.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 06, 2020
Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 23, 2019
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical genitourinary cancer
Published: December 13, 2019
Last Updated: 09/26/2026